Stocks · Healthcare · Biotechnology
Black Diamond Therapeutics, Inc. BDTX
$1.89 +0.53% Close, Oct 2, 2026 · NASDAQ · Market cap $108.3M
Weak trendExpensive vs sector
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $-0.74, down 421.7% year over year.
- The stock is 61% below its highest close of the past year.
- Over the past year the stock returned -49.2%, behind the S&P 500 by 64.3 percentage points.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 2%
- EPS growth (TTM, YoY)Bottom 6%
- FCF growth (TTM, YoY)Bottom 2%
- Revenue growth accelerationTop 46%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 29%
- Accruals (lower is better)Top 40%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 19%
- Free-cash-flow yieldBottom 17%
- EBITDA / enterprise valueBottom 18%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 9%
- 6-month returnBottom 23%
- 1-year return vs S&P 500Bottom 10%
- Distance from 52-week highBottom 15%
- Trend checklist (0–4)Bottom 14%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 49%
- Consecutive EPS beatsTop 35%
- Share of analysts rating BuyTop 26%
- Upside to consensus price targetTop 3%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 30%
- Maximum drawdown, 3 yearsBottom 27%
- Beta vs S&P 500 (lower is better)Bottom 8%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -100.0% | -100.0% | → |
| EPS growth (YoY) | -1366.7% | -421.7% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -100.0% | -100.0% | → | Bottom 2% |
| EPS growth (TTM, YoY) | -421.7% | -1366.7% | ↑ | Bottom 6% |
| Return on invested capital | -45.9% | — | Bottom 29% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -8.4%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 0.06%
- Shareholder yield
- 0.06%
- Share count change, 1 year
- +1.0%
- Share count change, 3-year CAGR
- +16.3%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 7 of 8
- Average EPS surprise, last 4
- +2.9%
- Average 2-day reaction, last 8
- +0.7%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $11.83
- Target vs current price
- +525.9%
- Analysts with a rating
- 11
- Share rating Buy or Strong Buy
- 91%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 5, 2026 | +13.0% | +0.6% | +17.4% | +14.6% | — |
| May 7, 2026 | +11.1% | -3.5% | +1.4% | -25.9% | -38.3% |
| Mar 16, 2026 | -44.4% | +3.3% | -0.5% | +28.3% | -10.4% |
| Nov 6, 2025 | +31.8% | +2.8% | +25.8% | -30.0% | -34.9% |
| Aug 7, 2025 | +24.0% | -15.2% | +3.0% | +6.7% | +42.0% |
| May 12, 2025 | +4800.0% | +6.7% | +18.9% | +51.2% | +64.0% |
| Mar 6, 2025 | +9.7% | +2.2% | -3.8% | -15.1% | +18.3% |
| Nov 5, 2024 | +24.3% | +8.7% | +13.0% | -17.4% | -18.1% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | -$0.17 | -$0.20 | +13.0% | — |
| May 7, 2026 | -$0.16 | -$0.18 | +11.1% | — |
| Mar 16, 2026 | -$0.26 | -$0.18 | -44.4% | — |
| Nov 6, 2025 | -$0.15 | -$0.22 | +31.8% | — |
| Aug 7, 2025 | -$0.19 | -$0.25 | +24.0% | — |
| May 12, 2025 | $0.98 | $0.02 | +4800.0% | $70.0M |
| Mar 6, 2025 | -$0.28 | -$0.31 | +9.7% | — |
| Nov 5, 2024 | -$0.28 | -$0.37 | +24.3% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| Free-cash-flow yield | -29.56% | — | — | Bottom 17% |
| Earnings yield | -39.15% | — | — | Bottom 19% |
P/E over the past five years
Range 5.8× – 29.2× since Mar 31, 2025. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- +2.0%
- 200-day average slope (20 days)
- -5.7%
- Distance from 50-day average
- -4.5%
- Distance from 200-day average
- -16.7%
- RSI (14)
- 42.8
- Relative volume
- 0.83×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 45.1%
- Volatility vs own 5-year history
- 1th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 2.27
- Correlation with S&P 500
- 0.50
- Current drawdown from 1-year high
- -61.2%
- Maximum drawdown, 3 years
- -83.1%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Nov 11, 2020 | Apr 8, 2025 | -96.4% | 1105 days | Not yet recovered |
| Oct 9, 2020 | Oct 20, 2020 | -12.8% | 7 days | 15 days (Nov 10, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $108.3M
- EPS, diluted (TTM)
- -$0.74
- Revenue (TTM)
- $0
- 52-week range
- $1.60 – $4.94
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $70.0M |
| Gross profit | $0 | $0 | -$437,000 | $0 | $69.7M |
| Operating income | -$126.9M | -$92.8M | -$86.5M | -$78.8M | $19.9M |
| Net income | -$125.6M | -$91.2M | -$82.4M | -$69.7M | $22.4M |
| EPS (diluted) | -$3.47 | -$2.52 | -$1.88 | -$1.27 | $0.39 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $70.0M | $0 | $0 | $0 | $0 | $0 |
| Net income | -$15.6M | -$16.0M | $56.5M | -$10.6M | -$8.5M | -$15.1M | -$9.0M | -$9.9M |
| EPS (diluted) | -$0.28 | -$0.28 | $0.98 | -$0.19 | -$0.15 | -$0.26 | -$0.16 | -$0.17 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$100.1M | -$85.1M | -$66.7M | -$62.3M | $29.6M |
| Capital expenditure | -$2.7M | -$192,000 | -$33,000 | $0 | $0 |
| Free cash flow | -$102.9M | -$85.3M | -$66.8M | -$62.3M | $29.6M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $729,000 | $177,000 | $71.8M | $24.5M | -$146,000 |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $110.5M
- Total assets
- $125.0M
- Total liabilities
- $28.9M
- Total debt
- $17.0M
- Net debt
- -$2.2M
- Shareholders’ equity
- $96.1M
As of Jun 30, 2026 (filed Aug 5, 2026).
Short interest
- Shares sold short
- 5,147,935
- Days to cover
- 10.13
- Change vs previous report
- -15.9%
FINRA short interest, settlement date Sep 15, 2026.